Get the Stockscreener App
1.42
4.70%
-0.07
After Hours:
1.37
-0.05
-3.52%
Metavia Inc stock is traded at $1.42, with a volume of 122.05K.
It is down -4.70% in the last 24 hours and down -11.80% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
See More
Previous Close:
$1.49
Open:
$1.43
24h Volume:
122.05K
Relative Volume:
0.48
Market Cap:
$7.23M
Revenue:
-
Net Income/Loss:
$-12.97M
P/E Ratio:
-0.254
EPS:
-5.5898
Net Cash Flow:
$-15.70M
1W Performance:
+15.45%
1M Performance:
-11.80%
6M Performance:
-88.16%
1Y Performance:
-84.06%
1-Day Range:
$1.3902
$1.4779
1-Week Range:
$1.17
$1.60
52-Week Range:
$1.17
$19.03
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.42 | 7.59M | 0 | -12.97M | -15.70M | -5.5898 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
Investment Recap: What is the next catalyst for MetaVia IncInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
Performance Recap: Is MetaVia Inc a cyclical or defensive stockDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
MetaVia (MTVA) Begins Patient Dosing in Phase 1 Clinical Trial - GuruFocus
MetaVia Doses First Patient in Higher-Dose Phase 1 Trial of Dual GLP-1/Glucagon Agonist DA-1726 for Obesity Treatment 1 - Minichart
MetaVia Advances DA-1726 Obesity Trial With First Patient - TipRanks
MetaVia begins higher-dose trial of obesity drug DA-1726 By Investing.com - Investing.com India
MetaVia, LifeMD, Nike - TradingView — Track All Markets
MetaVia begins higher-dose trial of obesity drug DA-1726 - Investing.com
MetaVia doses first patient in higher‑dose Phase 1 DA-1726 study; data due Q4 2026 - TradingView — Track All Markets
MetaVia (Nasdaq: MTVA) doses first patient in higher-dose DA-1726 obesity trial - Stock Titan
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity - PR Newswire
Weekly Trades: Is MetaVia Inc in a consolidation phaseLayoff News & High Return Stock Watch Alerts - baoquankhu1.vn
MetaVia Inc. (MTVA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Update Recap: Is MetaVia Inc currently under institutional pressureMarket Trend Report & Community Consensus Picks - baoquankhu1.vn
MetaVia (NASDAQ: MTVA) registers resale of 936,846 shares - Stock Titan
[EFFECT] MetaVia Inc. SEC Filing - Stock Titan
MTVA Technical Analysis & Stock Price Forecast - Intellectia AI
MTVA Stock Price, Quote & Chart | METAVIA INC (NASDAQ:MTVA) - ChartMill
Market Recap: Can MetaVia Inc continue delivering strong returns2026 Geopolitical Influence & Free Community Consensus Stock Picks - baoquankhu1.vn
Entry Recap: Can MetaVia Inc continue delivering strong returnsPortfolio Update Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
[POS AM] MetaVia Inc. SEC Filing - Stock Titan
1,896,385 Common Stock of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com
29,514 Restricted Stock Units of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Market Trends: Can MetaVia Inc continue delivering strong returnsMarket Risk Analysis & Smart Swing Trading Alerts - baoquankhu1.vn
MTVA PE Ratio & Valuation, Is MTVA Overvalued - Intellectia AI
MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026… - scr.zacks.com
Portfolio Shifts: Can MetaVia Inc stock outperform in a bear market2026 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
MetaVia stock price target lowered to $20 by H.C. Wainwright - Investing.com UK
Bearish Setup: Is now the right time to enter MetaVia IncMarket Movers & Fast Gaining Stock Reports - baoquankhu1.vn
Buy Signal: Is now the right time to enter MetaVia IncQuarterly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Can MetaVia Inc stock outperform in a bear marketWeekly Gains Summary & Smart Swing Trading Alerts - baoquankhu1.vn
H.C. Wainwright cuts MetaVia stock price target to $20 on dilution - Investing.com
H.C. Wainwright cuts MetaVia stock price target to $20 on dilution By Investing.com - Investing.com India
Big Picture: Does MetaVia Inc outperform in volatile markets2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
MetaVia Inc 2025 Annual Report: Clinical Progress, Risk Factors, and Cardiometabolic Drug Pipeline Overview - Minichart
MetaVia Updates Investor Strategy for Obesity and MASH - TipRanks
MetaVia Reports Positive 2025 Financial Results and Advances DA-1726 & Vanoglipel Clinical Programs for Obesity and MASH - Minichart
MTVA: Promising obesity and MASH therapies advance with strong early data and major market potential - TradingView
MTVA: Strong clinical progress in obesity and MASH with robust pipeline and solid financial footing - TradingView
MetaVia (MTVA) updates March 2026 corporate investor presentation - Stock Titan
MetaVia (MTVA) 2025 Financial Update - AlphaStreet
MetaVia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MetaVia Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MetaVia: Cash position adequate to fund operations into 4Q26 - TipRanks
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update - The AI Journal
Metavia Reports Year End 2025 Financial Results And Provides Corporate Update - TradingView
MetaVia (NASDAQ: MTVA) highlights progress in MASH and obesity trials - Stock Titan
MTVA: Strong clinical progress and improved financials position the pipeline for key 2026 milestones - TradingView
MetaVia (Nasdaq: MTVA) trims 2025 loss, extends cash and advances obesity drug - Stock Titan
MetaVia Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):